An International Randomised Trial of Celecoxib versus Celecoxib plus Difluoromethylornithine in Patients with Familial Adenomatous Polyposis | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
scientific articles

An International Randomised Trial of Celecoxib versus Celecoxib plus Difluoromethylornithine in Patients with Familial Adenomatous Polyposis

key information

source: Gut Journal

year: 2015

authors: Patrick M. Lynch, Carol A. Burke, Robin Phillips, Jeffrey S. Morris, Xuemei Wang, Jun Liu, Rebecca Slack, Sherri Patterson

summary/abstract:

BACKGROUND AND AIM : Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any.

METHODS : The primary endpoint was % change in adenoma count in a defined field. Secondary endpoints were adenoma burden (weighted by adenoma diameter) and video review of entire colon/rectal segments. Adverse event (AEs) were monitored by National Cancer Institution toxicity criteria.

RESULTS : 112 subjects were randomised: 60 men and 52 women at a mean age of 38 years. For the 89 patients who had landmark-matched polyp counts available at baseline and 6 months, the mean % change in adenoma count over the 6 months of trial was -13.0% for CXB+DFMO and -1.0% for CXB (p=0.69). Mean % change in adenoma burden was -40% (CXB+DFMO) vs -27% (CXB) (p=0.13). Video-based global polyp change was -0.80 for CXB+DFMO vs -0.33 for CXB (p=0.03). Fatigue was the only significant AE, worse on the CXB arm (p=0.02).

CONCLUSIONS : CXB combined with DFMO yielded moderate synergy according to a video-based global assessment. No significant difference in adenoma count, the primary endpoint, was seen between the two study arms. No evidence of DFMO-related ototoxicity was seen. There were no adverse cardiovascular outcomes in either trial arm and no significant increase in AEs in the CXB+DFMO arm of the trial. Differences in outcomes between primary and secondary endpoints may relate to sensitivity of the endpoint measures themselves.

TRIAL REGISTRATION NUMBER : ClinicalTrials.gov number N01-CN95040.

organisation: The University of Texas M.D. Anderson Cancer Center, Cleveland Clinic, St. Mark's Hospital, Mayo Clinic, Rambam Medical Center, Hvidore Hospital, The National Cancer Institute

DOI: 10.1136/gutjnl-2014-307235

abstract source full text source